News & Media

8/30/2016 | Press Release Metamark Receives Positive Medicare Final Coverage Decision for ProMark

Metamark Genetics, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses novel molecular diagnostic technologies, has issued final local coverage determination (LCD) for ProMark®, the first and only proteomic prognostic test for early-stage prostate cancer.

read more
3/10/2016 | Press Release ProMark® Prostate Cancer Prognostic now included in NCCN Guidelines

Metamark, a leader in commercializing high-value urologic oncology products, today announced that ProMark®, the first and only protein-based prognostic test for early-stage prostate cancer, has been included in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

read more

Dr. Jerome P. Richie on Prostate Cancer Awareness

In support of Prostate Cancer Awareness and the important year-round message to stay aware and well-informed of the latest news and developments in the fight against prostate cancer, Metamark’s esteemed Chief Medical Officer, Dr. Jerome P. Richie, participated in a series of radio interviews nationwide to discuss various topics around prostate cancer awareness.

Listen to an interview:
   Blog Talk Radio, Ask Mom RN
   KTLF-AM, The Ron and Corey Morning Show
   WYCA-FM, Real Talk

See more interviews.